Alembic Pharmaceuticals Ltd - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2021, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
Alembic Pharma gets USFDA nod for generic Nitrofurantoin capsules
The company has received final approval from the US Food Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Nitrofurantoin capsules, USP in the strengths of 25 mg, 50 mg and 100 mg, Alembic Pharma said in a regulatory filing. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st July, 2021 till 48 hours after the declaration of the unaudited financial results for the quarter ended 30th June, 2021. The date of the Board Meeting for inter alia considering the unaudited financial results for the quarter ended 30th June, 2021 will be intimated in due course. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper on 25th June, 2021 in Business Standard. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of legal heir(s) of the registered shareholder(s) in vernacular language (Gujarati) newspaper on 23rd June, 2021 in Loksatta. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of the notice published in English and vernacular language (Gujarati) newspaper on 17th June, 2021 in Economic Times and Indian Express, English Edition and Financial Express Gujarati Edition informing the members inter alia about the Book Closure, dispatch of Annual Report for F.Y. 2020-21 and procedure for remote e-voting. We request you to kindly take the same on record.
Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for testosterone topical solution
The approved product is therapeutically equivalent to the reference listed drug product (RLD) Axiron Topical Solution of Eli Lilly and Company.